Atopic Dermatitis Clinical Trial
Official title:
Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes
Verified date | September 2021 |
Source | Studies&Me |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Atopic eczema is a common skin disorder affecting at least 2-3% of the western population. Atopic eczema cannot be cured and therefore treatment aims to alleviate the symptoms of the disease. Today, many different medical treatments are available: from mild hormone creams to harsh systemic treatments. The treatment chosen depends in part on the severity of the eczema and on the treatment response of the individual. This practice may mean that some people with eczema undergo unnecessary treatment courses with associated side effects. We know today that eczema has a hereditary component, and different areas have been identified in the hereditary material that appear to play a role. Although it is thought that variations in specific areas of the inheritance material may influence how eczema is expressed in the individual, the significance of these variations is far from clarified. The investigators want to increase the knowledge about atopic eczema, about the disease and how in the future we can organize the treatment of eczema based on knowledge of our genetic material. In this study, the investigators want to elucidate whether there is a correlation between specific variations in the genetic material and how the eczema is clinically expressed. In addition, the investigators want to assess whether reports with specific information about the individual's genetic material in relation to his or her lifestyle can help retain participants in research projects.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Informed consent has been signed - 18 years or older - Resident in the USA or Denmark - AD meeting the UK Diagnostic Criteria for Atopic Dermatitis - At least one visible AD lesion at the time of recruitment (as confirmed remotely through photo upload in screening) - Smartphone user with daily access to internet (WIFI or 3G/4G) - Willing to donate a DNA sample - Confirmed intention to comply with study protocol procedures Exclusion Criteria: - Female subjects that are pregnant (or plan to become so during the study period) or lactating - Active dermatological condition that may confound the diagnosis of AD and/or the assessment of disease activity - Unable to speak or understand English or Danish - Overlap with participation in interventional trials - No visible AD at time of screening - Any other reasons that in the investigator's opinion could: - Impede a subject's ability to complete the study period - Influence the objectivity or quality of the findings of the study |
Country | Name | City | State |
---|---|---|---|
Denmark | Studies&Me | Copenhagen | |
United States | 450 Broadway F4 | Redwood City | California |
Lead Sponsor | Collaborator |
---|---|
Studies&Me | Biotx.ai, Bispebjerg Hospital, Life&Brain, Stanford Health Care |
United States, Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation between environmental factors and AD flare ups | Passive data on geographical localisation, daily activity level and an approximation for length of sleep | 12 weeks | |
Other | Number of days on a weekly cycle of patient-use of medication/treatment | Number of days on a weekly cycle of patient-use of medication/treatment | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the SCORing Atopic Dermatitis (SCORAD) evaluated remotely through photos by investigator assessment. | SCORAD measures the severity of eczema on a scale from 0-103. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Three Item Severity Score (TIS) evaluated remotely through photos by investigator assessment. | TIS measures the severity of erythema, oedema/papulation and excoriation on a scale from 0-9. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Eczema Area and Severity Index (EASI) evaluated remotely through photos by investigator assessment. | EASI measures the severity and body surface area of eczema on a scale from 0-72. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)) evaluated remotely through photos by investigator assessment. | vIGA-AD measures the severity of eczema on a scale from 0-4. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Patient Oriented Eczema Measurement (POEM) questionnaire. | POEM measures the severity of eczema as experienced by the patient on a scale from 0-28. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Skindex-mini questionnaire. | Skindex-mini measures the symptomatic, emotional and functional aspects of an individual's skin disorder on a scale from 0-18. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Patient's Global Impression of Severity Numerical Rating System (PGIS-NRS) questionnaire. | PGIS-NRS measures the impression of severity of an individual's skin disorder on a scale from 0-10. | 12 weeks | |
Primary | Change in AD phenotype measured on a weekly basis for 12 weeks using the Eczema-related sleep quality NRS questionnaire. | Eczema-related sleep quality NRS measures the sleep quality, itch and dryness on a scale from 0-10. | 12 weeks | |
Primary | Change in AD phenotype measured by patient-perceived flare ups on a weekly basis for 12 weeks. | Number of days on a weekly basis with flare ups. | 12 weeks | |
Primary | Change in AD phenotype measured by the disease extent method on a weekly basis for 12 weeks. | Palm method to measure AD affected body surface area (0-100%). | 12 weeks | |
Primary | Change in AD phenotype measured by the Eczema Area and Severity Index (EASI) on a weekly basis for 12 weeks. | EASI measures the severity and body surface area of eczema on a scale from 0-72. | 12 weeks | |
Secondary | Personalized DNA lifestyle reports/information reports as an engagement tool in clinical trials | Number of completers receiving DNA lifestyle reports/information reports at different time points will be compared to evaluate effect on retention. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |